Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Rhea-AI Summary

Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.

The study will compare these analogs with Bryostatin in SCI treatment. Synaptogenix holds exclusive rights to these PUFA analogs, which have shown promise in earlier pre-clinical testing for various neurodegenerative diseases. Like Bryostatin-1, these analogs activate the enzyme PKC epsilon (PKC ε), but at a different site, potentially offering a next-generation treatment for neurodegenerative conditions.

Positive

• New collaboration with LSU Health New Orleans for pre-clinical testing of PUFA analogs in spinal cord injury treatment
• Received US Patent No. 12,016,837 for PUFA analogs in treating neurodegenerative diseases
• Exclusive rights to PUFA analogs with potential as follow-on drug candidates
• Earlier pre-clinical testing showed positive results in various neurodegenerative disease processes

Negative

• None.

Medical Research Analyst

Synaptogenix's collaboration with LSU Health New Orleans to study their PUFA analogs in treating spinal cord injuries (SCI) is a notable step forward in the field of neurodegenerative disease research. The focus on PUFA analogs, which have previously shown promise in pre-clinical studies for conditions like Alzheimer's disease, adds a layer of credibility and potential to this endeavor. The activation of PKC ε (Protein Kinase C epsilon) is a key mechanism here. PKC ε is involved in various neural processes, including neuroprotection, synaptic plasticity and anti-inflammatory responses. The structural difference between PUFA analogs and Bryostatin-1, another PKC ε activator, suggests that these compounds might offer unique therapeutic benefits or improved safety profiles. This diversification is important in drug development, as it may lead to compounds with fewer side effects or enhanced efficacy.

For investors, this collaboration indicates that Synaptogenix is actively expanding its research horizons and leveraging academic partnerships to validate its drug candidates. Such collaborations can boost a company's credibility and lead to faster, more rigorous testing processes. However, it’s important to note that this is still in the pre-clinical stage, meaning the road to market approval is long and fraught with scientific and regulatory hurdles. Investors should consider the broader context, including Synaptogenix's financial health and the competitive landscape in neurodegenerative disease treatments, when evaluating this news.

Market Research Analyst

The announcement of a new US patent covering Synaptogenix's PUFA analogs emphasizes the company's strategic focus on intellectual property (IP) to protect its innovations. Patents are vital in the biopharmaceutical sector as they provide a competitive edge and can attract potential partnerships or acquisitions. This new patent underlines Synaptogenix's commitment to developing proprietary compounds, which could deter competitors and provide a solid foundation for future revenue streams if these drug candidates prove successful.

From an investor perspective, securing patents can enhance the company's valuation by demonstrating a forward-thinking approach to IP management. However, while the issuance of a patent is a positive development, it doesn’t guarantee commercial success. The effectiveness of these analogs in clinical trials, the ability to navigate regulatory landscapes and the company's capacity to market these treatments will ultimately determine their financial impact. Investors should keep a balanced view, considering both the potential upside and the inherent risks in drug development.

Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs

New patent covers proprietary analogs in the treatment of neurodegenerative diseases

NEW YORK, July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases,' covering its family of analogs. The studies will compare the analogs with Bryostatin in SCI.

"We are excited to begin this new collaboration with Synaptogenix to test the regenerative properties of Bryostatin and related compounds on our preclinical model of Spinal Cord Injury," stated Dr. Nicolas Bazan, Director, Neuroscience Center of Excellence, LSU Health New Orleans. 

"Dr. Nicolas Bazan is a world-renowned neuroscientist with an extensive body of  innovative research on neuroprotection and brain damage dating over three decades," said Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix. "We look forward to a robust study of our PUFA drug prototypes at his LSU Health New Orleans neuroscience lab. We believe these assets represent a potential source for follow-on drug candidates," Dr. Tuchman added. 

Synaptogenix holds exclusive rights to its PUFA analogs pursuant to a licensing agreement with Cognitive Research Enterprises, Inc. (CRE), formerly known as the Blanchette Rockefeller Neurosciences Institute.

"Earlier pre-clinical testing by CRE showed positive results from the PUFA analogs in slowing or reversing several neurodegenerative disease processes in Alzheimer's disease, and positive outcomes in synaptogenesis, anti-amyloid and anti-tau tangles, and prevention of neuronal death," said Dr. Daniel Alkon, President and CSO of Synaptogenix. "We are developing and patenting this class of compounds as a next-generation treatment for neurodegenerative diseases."

Like Bryostatin-1, the PUFA analogs are activators of the enzyme PKC epsilon (PKC ε), but the analogs are structurally different from Bryostatin-1 and activate PKC ε at a different site on the enzyme. PKC ε activation has been shown in preclinical in vivo models to play a key role in slowing or reversing several neurodegenerative disease processes in stroke, Alzheimer's disease (AD), ALS (Lou Gehrig's disease) and spinal cord injury.

About Synaptogenix

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that the Company will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's patent portfolio, the Company's inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company's raw materials, existing or increased competition, stock volatility and illiquidity, and the Company's failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Contact

800-811-5591
ir@synaptogen.com

 

View original content:https://www.prnewswire.com/news-releases/synaptogenix-announces-new-collaboration-with-lsu-health-new-orleans-for-study-of-proprietary-analogs-in-spinal-cord-injury-302200323.html

SOURCE Synaptogenix, Inc.

FAQ

What is Synaptogenix's new collaboration for PUFA analogs testing?

Synaptogenix (SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to conduct pre-clinical testing of its polyunsaturated fatty acid (PUFA) analogs as a potential treatment for spinal cord injury (SCI).

What patent did Synaptogenix (SNPX) recently receive for its PUFA analogs?

Synaptogenix (SNPX) recently received US Patent No. 12,016,837 titled 'Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases,' covering its family of PUFA analogs.

How do Synaptogenix's (SNPX) PUFA analogs compare to Bryostatin-1?

Like Bryostatin-1, Synaptogenix's (SNPX) PUFA analogs activate the enzyme PKC epsilon (PKC ε). However, the analogs are structurally different from Bryostatin-1 and activate PKC ε at a different site on the enzyme, potentially offering a next-generation treatment for neurodegenerative diseases.

What were the results of earlier pre-clinical testing of Synaptogenix's (SNPX) PUFA analogs?

Earlier pre-clinical testing of Synaptogenix's (SNPX) PUFA analogs showed positive results in slowing or reversing several neurodegenerative disease processes in Alzheimer's disease, and positive outcomes in synaptogenesis, anti-amyloid and anti-tau tangles, and prevention of neuronal death.